CONCLUSIONS	Treatment with efalizumab establishes successful recompartmentalization of T-cell subsets with modest clinical efficacy after 12 weeks , whereas in etanercept-treated patients , a significant clinical response is no guarantee for significant changes in T-cell subsets in the different compartments .\